[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, mogamulizumab has been shown to be an effective treatment for cutaneous T-cell lymphoma (CTCL). Document [0] states that mogamulizumab is one of the promising first-line therapies for advanced CTCL, and Document [1] mentions that mogamulizumab has been shown to be an effective and well-tolerated therapy for patients with relapsed and refractory MF/SS. Additionally, Document [7] discusses the approval of mogamulizumab by the FDA for the treatment of adult patients with relapsed or refractory CTCL. Therefore, the answer is A. yes, mogamulizumab can be used for the treatment of cutaneous T-cell lymphoma.\", \"answer_choice\": \"A\"}"
]